
|Articles|June 21, 2004
Drug provides relief to those with overactive bladder
The FDA recently approved trospium (Sanctura, Indevus Pharmaceuticals/Odyssey Pharmaceuticals) for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency. The product launch of trospium is expected to take place during the third quarter of 2004.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Reaffirms Strict Regulations Amid GLP-1 Compounding Concerns
2
Tryptyr Increases Tear Production in Dry Eye Disease
3
Bipartisan Legislation Aims to Address Consolidation and Vertical Integration of PBMs
4
Cigna to Remedy Years of Unfair Business Practices with Patients and Pharmacies
5




































